ライフサイエンスコーパス: pooled odds ratio

1 sis, and biomarkers were ranked according to pooled odds ratio.

2 62R was not associated with type 2 diabetes (pooled odds ratio 0.97 [95% CI 0.88-1.08], P = 0.63).

3 were just as likely to accept HBT as women (pooled odds ratio = 0.84; 95% CI: 0.56-1.26) (tau(2) = 0

4 reduced the incidence of fungal infections (pooled odds ratio, 0.44; 95% confidence interval, 0.27-0

5 s were significant only for EBV-positive HL (pooled odds ratio, 0.56; 95% confidence interval, 0.35 t

6 ers who had the symptom under investigation (pooled odds ratio = 1.61, 95% confidence interval: 1.36,

7 moderately increased risk for spina bifida (pooled odds ratio = 1.8; 95% confidence interval: 1.4, 2

8 with an increased risk of childhood asthma (pooled odds ratio, 1.34 [95% CI, 1.15-1.57], 1.32 [95% C

9 2.4% and in chronic kidney disease was 2.7%; pooled odds ratio, 1.6 (95% confidence interval, 1.3-1.8

10 05; P < .001); the benefit remained similar (pooled odds ratio, 1.96) when GIMEMA MM-BO2005 data were

11 were an independent predictor of death; the pooled odds ratio (12 studies) was 1.7 (95% confidence i

12 own to be significantly associated with IPV (pooled odds ratio 2.97, 95% CI 2.39 to 3.69).

13 y also appears to be a moderate risk factor (pooled odds ratio = 2.0; 95% confidence interval: 1.5, 2

14 compared with similar patients without VAP (pooled odds ratio, 2.03; 95% confidence interval, 1.16-3

15 s 53% and in chronic kidney disease was 73%; pooled odds ratio, 2.7 (95% confidence interval, 2.1-3.4

16 ed the risk for ACT; namely ABCC2 rs8187710 (pooled odds ratio: 2.20; 95% CI: 1.36-3.54), CYBA rs4673

17 than those below the threshold value (36%) (pooled odds ratio, 3.3; 95% confidence interval, 1.7-6.3

18 ose diarrhea was due to nonepidemic strains (pooled odds ratio, 4.35; 95 percent confidence interval,

19 The pooled odds ratio (95% confidence interval) for atrial f

20 Pooled odds ratios, according to HCC surveillance status

21 Pooled odds ratios and 95% CI were calculated by random-

22 Pooled odds ratios and 95% confidence intervals were est

23 simulation with Gibbs sampling, calculating pooled odds ratios and associated 95% confidence interva

24 ndom-effects model was used to calculate the pooled odds ratios based on the results from the heterog

25 odel was used to pool the data and calculate pooled odds ratios (endovascular vs open surgical repair

26 The pooled odds ratio estimate using 18 CRP genetic instrume

27 Pooled odds ratio for cardiotoxicity was 1.38 (95% CI, 1

28 PCSK9 LOF variants were associated with a pooled odds ratio for coronary heart disease of 0.51 (95

29 The pooled odds ratio for cross-sectional studies was 1.60 (

30 The pooled odds ratio for developing acute respiratory distr

31 evalence was 11.8% (95% CI 11.6-12.0) with a pooled odds ratio for HIV infection of 13.5 (95% CI 10.0

32 The pooled odds ratio for malignancy was 3.3 (95% confidence

33 Compared with noncurrent users, the adjusted pooled odds ratio for MI in current OC users was 0.94 (9

34 Compared with never users, the adjusted pooled odds ratio for MI was 0.56 (0.21, 1.49) in curren

35 y department triage (< 3 hr reference) had a pooled odds ratio for mortality of 1.16 (0.92-1.46; p =

36 s/shock recognition (< 1 hr reference) had a pooled odds ratio for mortality of 1.46 (0.89-2.40; p =

37 for ever vs never e-cigarette users, and the pooled odds ratio for past 30-day cigarette smoking at f

38 The pooled odds ratio for physician-diagnosed sciatica was 1

39 In a conventional meta-analysis, the pooled odds ratio for sensitisation was estimated as 0.2

40 After adjusting for these, the pooled odds ratio for sensitisation was estimated as 0.3

41 oral risk factors for cigarette smoking, the pooled odds ratio for subsequent cigarette smoking initi

42 For each biomarker, pooled odds ratios for clinical outcome were calculated

43 There was no increased mortality in the pooled odds ratios for each hourly delay from less than

44 Pooled odds ratios for ever use among 18 heterogeneous s

45 For the cross-sectional studies, the pooled odds ratio from the random-effects model was 1.18

46 Effects were summarized as pooled odds ratios in a random-effects model.

47 With 500 accumulated patients, the pooled odds ratio may change by 0.6- to 1.7-fold in the

48 The pooled odds ratio (nine studies) for developing an infec

49 g random-effects meta-analyses, we estimated pooled odds ratios of the association of breastfeeding w

50 with a significantly reduced odds of atopy (pooled odds ratio (OR) 0.82; 95% confidence interval (CI

51 was positively associated with incident T2D [pooled odds ratio (OR) 3.59 (95% CI: 1.49, 8.64, ptrend

52 oking during pregnancy and ASD in offspring (pooled odds ratio (OR) = 1.16, 95% CI: 0.97-1.40).

53 Both overweight (pooled odds ratio (OR) = 1.23, 95% confidence interval (

54 s and random-effects models to calculate the pooled odds ratio (OR) and 95% confidence interval (CI)

55 The pooled odds ratio (OR) for mortality risk in HAV superin

56 iance weighted method was used to estimate a pooled odds ratio (OR) for the effect of a 5-kg/m2 highe

57 d risk of CRC with exposure to oral BPs with pooled odds ratio (OR) of 0.87 (95% CI, 0.78 to 0.97).

58 g a random-effects model, and represented by pooled odds ratio (OR) with 95% confidence intervals (CI

59 We estimated pooled odds ratios (OR) and 95% confidence intervals (CI

60 The pooled odds ratios (OR) and the 95% confidence intervals

61 We calculated pooled odds ratios (OR), pooled risk ratios (RR), and 95

62 We calculated pooled odds ratios (OR), pooled risk ratios (RR), and 95

63 ated with reduced risk of colorectal cancer (pooled odds ratio [OR] 0.62, 95% CI 0.58-0.67, p(sig)<0.

64 tion to aspirin reduced death due to cancer (pooled odds ratio [OR] 0.79, 95% CI 0.68-0.92, p=0.003).

65 and 5-year mortality versus absence of CSPH (pooled odds ratio [OR] for 3-year mortality: 2.09; 95% c

66 enotype was associated with reduced PD risk (pooled odds ratio [OR], 0.7; 95% confidence interval [CI

67 s associated with 11% increased odds of XFS (pooled odds ratio [OR], 1.11; 95% CI, 1.05-1.17; P < .00

68 ssociated with increased risk of cervicitis (pooled odds ratio [OR], 1.66 [95% confidence interval {C

69 iated with improved hand hygiene compliance (pooled odds ratio [OR], 1.82; 95% confidence interval [C

70 phically defined cases and control subjects (pooled odds ratio [OR]: 1.31, 95% confidence interval [C

71 were 76% more likely to be overweight/obese (pooled odds ratio [OR]: 1.76; 95% confidence interval [C

72 he risk of right bundle branch block (RBBB) (pooled odds ratio [OR]: 56.3; 95% CI: 11.6 to 273.9) alo

73 Pooled odds ratios (ORs) and 95% CIs were calculated for

74 Pooled odds ratios (ORs) and 95% confidence intervals (C

75 Random-effects meta-analysis obtained pooled odds ratios (ORs) and 95% confidence intervals (C

76 Pooled odds ratios (ORs) and 95% confidence intervals (C

77 Random effects model meta-analysis obtained pooled odds ratios (ORs) and 95% confidence intervals (C

78 ertainty due to between-study variation, the pooled odds ratios (ORs) and 95% credible intervals (CrI

79 Pooled odds ratios (ORs) and corresponding 95% confidenc

80 Random effects models were used to calculate pooled odds ratios (ORs) and investigate heterogeneity b

81 Data are reported as pooled odds ratios (ORs) by use of the generic inverse v

82 We estimated pooled odds ratios (ORs) for infection using random-effe

83 f genotype by calculating study specific and pooled odds ratios (ORs) in meta-analyses, and assessed

84 Pooled odds ratios (ORs) of inhibitor development for di

85 We calculated pooled odds ratios (ORs) using a random-effects model.

86 rived measures of association and calculated pooled odds ratios (ORs) using inverse-variance weighted

87 Pooled odds ratios (ORs) were estimated by either fixed

88 Pooled odds ratios (ORs) with 95% confidence intervals (

89 Pooled odds ratios (ORs) with corresponding confidence i

90 Data Extraction and Synthesis: Pooled odds ratios (ORs), 95% CIs, and P values were est

91 rmed using a fixed-effects model to estimate pooled odds ratios (ORs).

92 cts meta-analyses were performed to estimate pooled odds ratios (ORs).

93 effects meta-analyses were used to generate pooled odds ratios (ORs).

94 The pooled odds ratio per 5-year increase in age at last bir

95 ssociated with inability to balance for 5 s (pooled odds ratio per minor allele = 0.90, 95% CI: 0.82-

96 with an increased risk of borderline tumors (pooled odds ratio (pOR) = 1.32, 95% confidence interval

97 ith an increased risk of preschool wheezing (pooled odds ratio [pOR], 1.34; 95% CI, 1.25-1.43) and sc

98 e estimated and subsequently combined into a pooled odds ratio using a random-effects model.

99 We estimated pooled odds ratios using random-effect regression models

100 to one study; with that study excluded, the pooled odds ratio was 0.73 (95% CI: 0.64, 0.84) (Phetero

101 The pooled odds ratio was 1.15 (95% confidence interval, 0.7

102 A pooled odds ratio was calculated using a fixed-effects m

103 The pooled odds ratios were 0.78 (95% confidence interval: 0

104 ase-control and cross-sectional studies, the pooled odds ratios were 2.24 (95% confidence interval: 1

105 Pooled odds ratios were calculated for factors associate

106 The pooled odds ratios were determined using meta-analytic t

107 based on the random effects model to produce pooled odds ratios with 95% confidence intervals.